Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT
Rabah Redjoul, Anne Le Bouter, Vincent Parinet, et al.
The Lancet Haematology (2021) Vol. 8, Iss. 10, pp. e681-e683
Open Access | Times Cited: 74

Showing 1-25 of 74 citing articles:

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
Annika Fendler, Elisabeth G.E. de Vries, Corine H. GeurtsvanKessel, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 6, pp. 385-401
Open Access | Times Cited: 179
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)
Simone Cesaro, Per Ljungman, Małgorzata Mikulska, et al.
Leukemia (2022) Vol. 36, Iss. 6, pp. 1467-1480
Open Access | Times Cited: 107
Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients
Alexis Maillard, Rabah Redjoul, Marion Klemencie, et al.
Blood (2021) Vol. 139, Iss. 1, pp. 134-137
Open Access | Times Cited: 68
Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults
Addi J. Romero‐Olmedo, Axel Schulz, Svenja Hochstätter, et al.
Nature Microbiology (2022) Vol. 7, Iss. 2, pp. 195-199
Open Access | Times Cited: 65
Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting
Moshe Mittelman, Ori Magen, Noam Barda, et al.
Blood (2021) Vol. 139, Iss. 10, pp. 1439-1451
Open Access | Times Cited: 63
Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients
Sabine Haggenburg, Birgit I. Lissenberg‐Witte, Rob van Binnendijk, et al.
Blood Advances (2022) Vol. 6, Iss. 5, pp. 1537-1546
Open Access | Times Cited: 56
Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients
Muhammad Bilal Abid, Micah Rubin, Nathan A. Ledeboer, et al.
Cancer Cell (2022) Vol. 40, Iss. 4, pp. 340-342
Open Access | Times Cited: 43
SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination
José Luís Piñana, Rodrigo Martino, Lourdes Vázquez, et al.
Bone Marrow Transplantation (2023) Vol. 58, Iss. 5, pp. 567-580
Open Access | Times Cited: 24
Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma
Julia E. Wiedmeier, Madiha Iqbal, Allison Rosenthal, et al.
Clinical Lymphoma Myeloma & Leukemia (2023) Vol. 23, Iss. 6, pp. 456-462
Open Access | Times Cited: 23
Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article
Jérôme Barrière, Michel Carlès, Clarisse Audigier-Valette, et al.
European Journal of Cancer (2021) Vol. 162, pp. 182-193
Open Access | Times Cited: 52
Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients
Lorenzo Canti, Stéphanie Humblet‐Baron, Isabelle Desombere, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 51
Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients
Xi Wu, Lu Wang, Lu Shen, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 37
Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients
Muneyoshi Kimura, Victor H. Ferreira, Sagar Kothari, et al.
Transplantation and Cellular Therapy (2022) Vol. 28, Iss. 10, pp. 706.e1-706.e10
Open Access | Times Cited: 35
Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis
Aaron Shengting, Ainsley Ryan Yan Bin Lee, Ryan Yong Kiat Tay, et al.
European Journal of Cancer (2022) Vol. 172, pp. 65-75
Open Access | Times Cited: 34
Immunity to SARS-CoV-2: What Do We Know and Should We Be Testing for It?
Anisha Misra, Elitza S. Theel
Journal of Clinical Microbiology (2022) Vol. 60, Iss. 6
Open Access | Times Cited: 31
CD19+IgD+CD27- Naïve B Cells as Predictors of Humoral Response to COVID 19 mRNA Vaccination in Immunocompromised Patients
Eduard Schulz, Isabel Hodl, Patrick Forstner, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 34
SARS‐CoV‐2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine
Erdinç Yavuz, Özgür Günal, Eşe Başbulut, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 8, pp. 3768-3775
Open Access | Times Cited: 22
Immunity after COVID-19 Recovery and Vaccination: Similarities and Differences
Dorota Kamińska, Dominika Dęborska−Materkowska, Katarzyna Kościelska−Kasprzak, et al.
Vaccines (2022) Vol. 10, Iss. 7, pp. 1068-1068
Open Access | Times Cited: 22
Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic hematopoietic stem cell transplantation
Sigrun Einarsdottir, Anna Martner, Malin Nicklasson, et al.
Haematologica (2022) Vol. 107, Iss. 6, pp. 1479-1482
Open Access | Times Cited: 21
Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients
Lorenzo Canti, Kevin K. Ariën, Isabelle Desombere, et al.
Cancer Cell (2022) Vol. 40, Iss. 4, pp. 335-337
Open Access | Times Cited: 20
Spike-Specific Memory B Cell Response in Hematopoietic Cell Transplantation Recipients following Multiple mRNA-1273 Vaccinations: A Longitudinal Observational Study
Elena Pettini, Annalisa Ciabattini, Fabio Fiorino, et al.
Vaccines (2024) Vol. 12, Iss. 4, pp. 368-368
Open Access | Times Cited: 4
How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies
Antoni Ribas, Madhav V. Dhodapkar, Katie M. Campbell, et al.
Blood Cancer Discovery (2021) Vol. 2, Iss. 6, pp. 562-567
Open Access | Times Cited: 26
Immunogenicity of SARS-CoV-2 vaccines in patients with cancer
Helen Kakkassery, Esme Carpenter, Piers Patten, et al.
Trends in Molecular Medicine (2022) Vol. 28, Iss. 12, pp. 1082-1099
Open Access | Times Cited: 19
Impaired humoral and cellular response to primary COVID‐19 vaccination in patients less than 2 years after allogeneic bone marrow transplant
Sam M. Murray, Maria Chiara Barbanti, Cori Campbell, et al.
British Journal of Haematology (2022) Vol. 198, Iss. 4, pp. 668-679
Open Access | Times Cited: 18
COVID‐19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)‐T‐cell therapy
Eleftheria Kampouri, Joshua A. Hill, M. Veronica Dioverti
Transplant Infectious Disease (2023) Vol. 25, Iss. S1
Closed Access | Times Cited: 10
Page 1 - Next Page

Scroll to top